Menu
We design and deliver methodologically rigorous evidence generation programmes, including clinical study design, systematic reviews, and real-world evidence. We support the full publication process—from protocol development and PROSPERO registration to congress presentations and peer-reviewed manuscripts—ensuring high-impact scientific visibility.
We ensure that strategy translates into real-world adoption by supporting product launches, stakeholder alignment, and market penetration.
We assess emerging molecules across the translational pathway to support licensing, acquisition, and investment decisions.
We identify new opportunities for approved therapies by aligning mechanism of action, clinical evidence, and real-world use.
We support prioritisation and regulatory pathways across global markets, with proven success in complex environments such as Brazil and Latin America.
We support the development and multi-market launches of biomarker-driven diagnostics, enabling patient stratification and more targeted treatment approaches.
We design and implement partnerships that connect academia and industry, supporting talent development, research strategies, and grant opportunities.
Our approach is grounded in end-to-end translational science:
We connect mechanism of action, clinical outcomes, and real-world practice to generate insights that are scientifically robust, commercially actionable, and effectively implemented.
We operate in areas where complexity demands integration:
We support clients across multiple geographies, combining global strategic insight with deep understanding of local market dynamics.
Our experience spans:
We bring global standards to local decision-making – and local insight to global strategy.
The Embedded Implementation Lead is a Pulsus role designed to connect strategy with execution. Embedded within client teams, it translates scientific and clinical strategy into actionable, locally tailored plans, aligning internal functions and engaging external stakeholders to ensure effective delivery. It does not replace field teams—it enables them to perform at their best, accelerating implementation and driving real-world impact.
As a boutique consultancy, Pulsus offers highly tailored, senior-led support adapted to each client’s needs. We combine strategic insight with hands-on execution, working flexibly across projects rather than applying standardised approaches.
An integrated leadership model combining preclinical science, clinical development, and real-world expertise.
Founder & Director, Translational Strategy
Mauricio Silva de Lima is the Founder of Pulsus Pharma Consultancy and leads its strategic direction across global markets. He has authored over 100 peer-reviewed publications and scientific presentations across key therapeutic areas.
With extensive experience in clinical development, medical affairs, regulatory strategy, and evidence generation – including scientific publications – he specialises in linking preclinical insights with clinical and real-world outcomes.
His work is grounded in rigorous, evidence-based methodologies, such as systematic reviews and meta-analyses, combined with implementation science to ensure that scientific innovation translates into meaningful clinical and commercial impact.
Preclinical and Translational Research Lead
Pedro Antonio Schmidt do Prado Lima is the Preclinical and Translational Research Lead at Pulsus Development, specialising in early-stage drug development and the critical evaluation of preclinical evidence.
With extensive experience supporting pharmaceutical programmes—particularly in collaboration with industry partners in Brazil—his work focuses on mechanism-of-action assessment, experimental models, and the rigorous appraisal of early scientific data to inform downstream development decisions.
In addition to his research background, Pedro brings significant clinical experience, enabling him to assess the clinical relevance of preclinical findings and anticipate challenges in their application. His work ensures that early scientific insights are grounded in both biological plausibility and clinical reality.
AI Medical Affairs & Clinical Development
Dr. Alf Bernhardt is a Senior Advisor to Pulsus Pharma Consultancy, bringing over 25 years of experience in oncology, hematology, and cell therapy. He advises pharmaceutical and biotech companies on medical affairs strategy, clinical development, evidence generation, and product launch execution.
He has held senior leadership roles at Roche, Seagen (Pfizer), and Takeda, leading global medical affairs across the product lifecycle, including major oncology launches and the build-out of European medical organisations.
His expertise spans medical affairs strategy, clinical development (Phase I–IV), KOL engagement, evidence generation, regulatory strategy, and product launch execution, with a focus on cell and gene therapy and the application of AI in medicine. His work supports the effective translation of scientific innovation into clinical adoption and real-world impact.
He is the founder of Alf Bernhardt Medical Consulting (Switzerland; abmedicalconsulting.ch) and serves as an independent consultant to NemetzGroup LLC (Boston).
Junior Consultant – Real-World Evidence & Data Analytics
Henrique Andrea de Lima is a Biomedical Sciences undergraduate at City St George’s, University of London. Fluent in English and Portuguese, this dual Brazilian-Italian citizen has lived across California, Switzerland, and the UK, bringing a global perspective to medical affairs.
Having interned within the Real-World Evidence (RWE) team at Roche Brazil, Henrique utilizes advanced statistical models and data manipulation tools (R, SQL, DBeaver) to drive evidence-based decision-making. Aligning perfectly with Pulsus’s focus on bottom-up evidence generation, he pairs these technical capabilities with a robust clinical research background, having co-authored psychiatric research on ADHD and routinely participated in conducting rigorous systematic reviews for evidence synthesis.
At Pulsus, strategy is developed through close integration of preclinical science, clinical development, and real-world practice. This ensures that early evidence is interpreted in a clinically meaningful context, supporting regulatory decision-making, market access, and effective implementation.
PPC brings 200+ years of experience in Health Care & Pharma
Seasoned executive with over 20 years of combined Medical Affairs & Commercial experience
Results-oriented leader with strong skills in strategic thinking and execution, shaped small, large, and complex organizations
SVP and Global Medical Head at a Gene Therapy biotech, VP/Medical Head and Region Europe Medical Head at two top 10 global pharma company
Over 35 years of experience in pharma working in preclinical and clinical research, medical affairs, regulatory affairs, and pharmacovigilance
Experience in various therapeutic areas, such as neuroscience, oncology and cardiovascular
Primary focus over the past 20 years on PV, involving inspections, operations, data analysis and new methodologies, safety agreements. Working directly with global health authorities on numerous multi-partner collaboration projects
Medical affairs professional with over 20 years experience at a national, regional and global level leading many medical affairs teams in multiple therapeutic areas
Results oriented and at home in primary, specialist, large as well as rare disease areas
Track record on extracting maximum value from medical affairs, working on launches, integrated evidence generation, pre-approval access, KOL engagement plans and more
Expertise in health regulation and health economics, health prices and reimbursements
Played several senior roles at ANVISA (the Brazilian National Health Surveillance Agency and regulatory body)
Formulated guidelines to Health Surveillance Systems, health policies and guidelines
World expert in psychopharmacology, genetics, and cellular therapy
Authored several scientific papers and book chapters
Demonstrated the extinction and non-consolidation of traumatic memory with the use of topiramate, pioneered the use of stem cells in the treatment and prevention of depression in animal models
Oncologist with over 20 years of experience in clinical practice
Led Departments of Clinical Oncology in renowned cancer hospitals in Brazil
Experience training resident physicians, post-graduate programs (MSc and PhD) and clinical research, participated directly in the training of more than 100 specialists
